Abstract
Obinutuzumab (Gazyva™) is an intravenously administered, humanized and glycoengineered, type II anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. It is approved in the US for use in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukaemia (CLL), and has been filed for approval in the EU in this indication. The antibody is based on GlycArt Biotechnology's (later Roche Glycart AG) proprietary GlycoMAb® technology, which uses glycoengineered antibodies that specifically increase antibody-dependent cellular cytotoxicity and thereby increase immune-mediated target cell death. Obinutuzumab is a type II anti-CD20 antibody that induces enhanced direct cell death. The monoclonal antibody is in worldwide phase III development with Roche and its subsidiaries, Genentech and Chugai Pharmaceutical, as well as Biogen Idec, for diffuse large B-cell lymphoma and non-Hodgkin's lymphoma generally, and is also in phase III development in countries outside of the US and EU for CLL.
References
Aug 27, 2005·Blood·Wolfgang HiddemannMichael Unterhalt
Oct 31, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yuki MoritokiM Eric Gershwin
Mar 3, 2010·Blood·Ekkehard MössnerPablo Umaña
Feb 19, 2011·Drugs & Aging·Valentin Goede, Michael Hallek
Mar 30, 2011·Blood·Gerhard NiederfellnerChristian Klein
Nov 17, 2011·Drugs·Julie E Chang, Brad S Kahl
Feb 23, 2012·Blood·Jamie HoneychurchTim M Illidge
Mar 21, 2012·Blood·Gilles SallesGuillaume Cartron
Mar 23, 2012·Blood·Laurie H SehnMichael Crump
Sep 1, 2012·Leukemia·V GoedeM Hallek
Sep 11, 2012·Current Opinion in Oncology·Till M Seiler, Wolfgang Hiddemann
Oct 11, 2012·Cancer Science·Michinori OguraTomomitsu Hotta
Dec 6, 2012·MAbs·Christian KleinGerhard Niederfellner
Feb 19, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sarwish RafiqJohn C Byrd
Apr 24, 2013·Therapeutic Advances in Hematology·Michele MerliFrancesco Passamonti
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gilles A SallesGuillaume Cartron
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck Andre MorschhauserGilles Andre Salles
Jul 12, 2013·Blood·John RadfordUmberto Vitolo
Jul 23, 2013·Molecular Cancer Therapeutics·Sylvia HerterChristian Klein
Mar 7, 2014·Current Opinion in Biotechnology·Mattheos A G Koffas, Jan Marienhagen
Aug 22, 2014·Blood·Guillaume CartronMichael Hallek
Citations
Sep 5, 2014·Drugs·Anthony Markham
Sep 25, 2014·Expert Review of Hematology·Tadeusz Robak
Jul 15, 2015·Expert Opinion on Emerging Drugs·Pawel RobakTadeusz Robak
Apr 5, 2016·Seminars in Oncology·Tadeusz RobakPawel Robak
Apr 16, 2015·Journal of Pharmaceutical Sciences·Liming Liu
Dec 1, 2015·Future Oncology·Craig ErkerMichael J Burke
Jul 28, 2015·Biotechnology Journal·Jennifer D KönitzerAnne B Tolstrup
Dec 20, 2014·Future Oncology·Abdulmunem AbulayhaIan Daniels
Nov 3, 2016·Biometrical Journal. Biometrische Zeitschrift·Elina AsikaniusHans Ulrich Burger
Jun 3, 2016·Lupus·M H C BiermannM Herrmann
Jan 26, 2017·Leukemia Research·Wei Wen ChienAbdel Aouacheria
Jul 5, 2017·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Minoru Tada, Akiko Ishii-Watabe
Mar 4, 2018·Scientific Reports·Masato KiyoshiAkiko Ishii-Watabe
Oct 6, 2018·Glycobiology·Renato MastrangeliHorst Bierau
Mar 11, 2020·Cells·Lorenzo BaroloMathieu Pernice
May 4, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Xiaojie YuMax Crispin
Jul 20, 2014·The Annals of Pharmacotherapy·Arpita Shah
Aug 26, 2021·Expert Opinion on Biological Therapy·Anurag Rathore, Himanshu Malani
Oct 30, 2021·Frontiers in Immunology·Andrew R CrowleyMargaret E Ackerman
Nov 5, 2021·Frontiers in Immunology·Kristina Zlatina, Sebastian P Galuska